Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

11 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-20

Study Completion Date

2023-07-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall purpose of this project is to establish the capability of screening for Angelman syndrome (AS) and Prader-Willi syndrome (PWS) in public health newborn screening (NBS) programs, with an aim of developing and validating a screening test for AS and PWS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-Invasive Screening for Fetal Aneuploidy

NCT02317965

Down Syndrome Edwards Syndrome

UNKNOWN

Baby Detect : Genomic Newborn Screening

NCT05687474

Systemic Primary Carnitine Deficiency Carnitine Palmitoyltransferase Deficiency 2 Congenital Adrenal Hyperplasia +121 more

COMPLETED

Early Check: Expanded Screening in Newborns

NCT03655223

Spinal Muscular Atrophy Fragile X Syndrome Fragile X - Premutation +182 more

ENROLLING_BY_INVITATION

Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA

NCT02109770

Microdeletion Syndromes Trisomy 21 Trisomy 18 +2 more

COMPLETED

Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor

NCT05742997

Preterm Birth

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project will have an assay development phase and an assay validation phase.

In the assay development phase, the investigators will develop a method of assessing SNRPN promoter (located in chromosome 15 q11-q13) methylation status using methylation-specific PCR coupled with a melting curve analysis with de-identified leftover DNA from routine newborn screening dried blood samples for severe combined immunodeficiency and spinal muscular atrophy.

In the assay validation phase, the investigators plan to assess the assay sensitivity and specificity using a set of DNA samples extracted from dried blood spots in each following group:

1. Healthy individuals
2. AS patients with genetic testing confirmation that the maternal copy of chromosome 15 q11-q13 is deleted, or that there are two paternal copies of chromosome 15 q11-q13 or imprinting center defect.
3. PWS patients with genetic testing confirmation that the paternal copy of chromosome 15 q11-q13 is deleted, or that there are two maternal copies of chromosome 15 q11-q13 or imprinting center defect.

For participants with AS or PWS, blood samples will be obtained via a self-administered finger prick performed in the participant's home. The participant will mail the sample to the researchers using a provided envelope. If the team is not able to reach the participant after two phone call attempts, the study team may approach them at their next clinic visit to assess interest in study participation. If participants opt to join the study at this clinic visit, the blood sample may be obtained in clinic.

For healthy controls, blood samples will be obtained via a self-administered finger prick, and participants will verbally respond to a brief demographic questionnaire.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angelman Syndrome Prader-Willi Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants with Angelman Syndrome (AS)

AS confirmed by molecular testing

Newborn Screening Assay

Intervention Type DIAGNOSTIC_TEST

The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:

* Is noninvasive
* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)
* Does not by design or intention introduce energy into a subject, and
* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.

Participants with Prader-Willi Syndrome (PWS)

PWS confirmed by molecular testing

Newborn Screening Assay

Intervention Type DIAGNOSTIC_TEST

The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:

* Is noninvasive
* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)
* Does not by design or intention introduce energy into a subject, and
* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.

Healthy Controls

Newborn Screening Assay

Intervention Type DIAGNOSTIC_TEST

The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:

* Is noninvasive
* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)
* Does not by design or intention introduce energy into a subject, and
* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Newborn Screening Assay

The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device. In this study, the testing involved with this assay fulfills the following criteria:

* Is noninvasive
* Does not require an invasive sampling procedure that presents significant risk (the finger prick is minimal risk)
* Does not by design or intention introduce energy into a subject, and
* Is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure, as participants will not receive results in this study.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with Angelman Syndrome, confirmed by molecular testing (deletion of maternal allele of chromosome 15q11-q13, paternal uniparental disomy, and imprinting center defects)
* Diagnosed with Prader-Willi Syndrome, confirmed by molecular testing (deletion of paternal allele of chromosome 15q11-q13, maternal uniparental disomy, and imprinting center defects)
* Angelman Syndrome or Prader Willi Syndrome: Current patient at UW Health in the Madison, Wisconsin metropolitan area
* Healthy controls 18 years old or older and have not received a diagnosis of Angelman syndrome or Prader Willi syndrome

Exclusion Criteria

* Angelman Syndrome/Prader Willi Syndrome: family requires a translator for medical visits
* Healthy Controls: Participants are unable to consent and complete study procedures in English.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes